<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294472</url>
  </required_header>
  <id_info>
    <org_study_id>MAU868-201</org_study_id>
    <nct_id>NCT04294472</nct_id>
  </id_info>
  <brief_title>A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amplyx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amplyx Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study will test the safety and efficacy of the investigational
      medication MAU868, compared to a placebo, in patients who have had a kidney transplant who
      have active BK virus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 10, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (weeks) to decrease of BKV plasma viral load by 1 log</measure>
    <time_frame>Study Week 1 - Study Week 12</time_frame>
    <description>The efficacy of MAU868 in treating BK viremia will be measured primarily by measuring the BK Viral Load in the plasma over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time (weeks) to first decrease of BKV plasma viral load to less than Lower Limit of Quantification (LLOQ)</measure>
    <time_frame>Study Week 1 - Study Week 12</time_frame>
    <description>The efficacy of MAU868 in treating BK viremia will be measured primarily by measuring the BK Viral Load in the plasma over time.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>BK Virus Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: MAU868 1350 mg IV approximately every 28 days for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: MAU868 6750 mg IV on Study Day 1 and then 1350 mg IV approximately every 28 days for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: MAU868 6750 mg IV approximately every 28 days for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 1, 2, 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose in water [D5W] IV delivered every 28 days for a total of 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAU868</intervention_name>
    <description>MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>250 mL D5W placebo IV to be labeled to match that of MAU868</description>
    <arm_group_label>Placebo Cohort 1, 2, 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a male or female 18 years of age or older.

          -  Recipient of a kidney (or kidney-pancreas) transplant within the year prior to
             enrollment

          -  Documented BKV viremia based on local or central laboratory testing within 10 days

        Exclusion Criteria:

          -  A BKV plasma viral load which has exceeded 10^3 copies/mL for &gt;4 months.

          -  A BKV plasma viral load of â‰¥ 10^7 copies/mL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sara Barbat</last_name>
    <phone>858-345-1755</phone>
    <email>sbarbat@amplyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Delos Santos, MD</last_name>
      <email>delossantos@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

